gti-2040
Nucleic acidexperimental
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2002 (NCT00056173)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Prostatic Neoplasms · Phase 2
Mechanism of action
- Ribonucleotide reductase small subunit mRNAANTISENSE INHIBITOR
Ribonucleotide reductase small subunit mRNA antisense inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297763 ↗
Also known as
- gti2040
- gti-2040
- gti-2040
- gti-2040
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00565058 | Phase 2 | Aug 1, 2007 | Aptose Biosciences Inc., Ohio State University |
| NCT00459212 | Phase 1 | Mar 1, 2007 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00087165 | Phase 2 | Jan 1, 2005 | National Cancer Institute (NCI), University of Toronto |
| NCT00084643 | Phase 1 | May 1, 2004 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00078962 | Phase 1 | Jan 1, 2004 | National Cancer Institute (NCI), University of Texas, San Antonio |
| NCT00074022 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2003 | National Cancer Institute (NCI), University of Toronto |
| NCT00068588 | Phase 2 | Oct 1, 2003 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00070551 | Phase 1 | Sep 1, 2003 | National Cancer Institute (NCI), Ohio State University |
| NCT00056173 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2002 | Aptose Biosciences Inc., University of Chicago, Wake Forest University |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 6 | 2 | 2003 |
| City of Hope National Medical Center | Academic/Hospital | 3 | 0 | 2 | 2003 |
| Aptose Biosciences Inc. | For profit | 2 | 2 | 1 | 2002 |
| Ohio State University | Academic/Hospital | 2 | 0 | 2 | 2003 |
| University of Toronto | Academic/Hospital | 2 | 1 | 1 | 2003 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Wake Forest University | Academic/Hospital | 1 | 0 | 1 | 2002 |
8 organizations
Page 1 / 1